204 related articles for article (PubMed ID: 7520169)
1. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.
Raphael SJ; McKeown-Eyssen G; Asa SL
Mod Pathol; 1994 Apr; 7(3):295-300. PubMed ID: 7520169
[TBL] [Abstract][Full Text] [Related]
2. Brief report: detection of high-molecular-weight cytokeratins in neoplastic and non-neoplastic thyroid tumors using microwave antigen retrieval.
Raphael SJ; Apel RL; Asa SL
Mod Pathol; 1995 Oct; 8(8):870-2. PubMed ID: 8552578
[TBL] [Abstract][Full Text] [Related]
3. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A
Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634
[TBL] [Abstract][Full Text] [Related]
4. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution.
Sahoo S; Hoda SA; Rosai J; DeLellis RA
Am J Clin Pathol; 2001 Nov; 116(5):696-702. PubMed ID: 11710686
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
6. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
Nasser SM; Pitman MB; Pilch BZ; Faquin WC
Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
[TBL] [Abstract][Full Text] [Related]
7. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma.
Tan A; Etit D; Bayol U; Altinel D; Tan S
Ann Diagn Pathol; 2011 Apr; 15(2):108-16. PubMed ID: 21315633
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical study of the expression of S-100 protein, epithelial membrane antigen, cytokeratin and carcinoembryonic antigen in thyroid lesions.
Mitselou A; Vougiouklakis TG; Peschos D; Dallas P; Boumba VA; Agnantis NJ
Anticancer Res; 2002; 22(3):1777-80. PubMed ID: 12168868
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis of the follicular variant of papillary thyroid carcinoma. Significance of immunohistochemistry].
Guyétant S; Michalak S; Valo I; Saint-André JP
Ann Pathol; 2003 Feb; 23(1):11-20. PubMed ID: 12743496
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation.
Atik E; Guray M; Gunesacar R; Ozgur T; Canda T
Indian J Cancer; 2014; 51(1):63-8. PubMed ID: 24947099
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
El Demellawy D; Nasr AL; Babay S; Alowami S
Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical study of type-1 blood antigen expressions in thyroid tumors: the significance for papillary carcinomas.
Kamoshida S; Ogane N; Yasuda M; Muramatsu T; Bessho T; Kajiwara H; Osamura RY
Mod Pathol; 2000 Jul; 13(7):736-41. PubMed ID: 10912932
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 is a presurgical marker of human thyroid carcinoma.
Orlandi F; Saggiorato E; Pivano G; Puligheddu B; Termine A; Cappia S; De Giuli P; Angeli A
Cancer Res; 1998 Jul; 58(14):3015-20. PubMed ID: 9679965
[TBL] [Abstract][Full Text] [Related]
15. [Cytokeratin expression of benign and malignant epithelial thyroid gland tumors. An immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies].
Schröder S; Wodzynski A; Padberg B
Pathologe; 1996 Nov; 17(6):425-32. PubMed ID: 9082363
[TBL] [Abstract][Full Text] [Related]
16. [Diagnostic contribution of HBME-1 and anti-cytokeratin-19 antibodies in thyroid pathology: a retrospective study of 163 cases].
Ziadi S; Trimeche M; Zermani R; Elmay A; Baltagi-Ben Jilani S
Tunis Med; 2005 May; 83(5):274-8. PubMed ID: 16044900
[TBL] [Abstract][Full Text] [Related]
17. Expression of D2-40 in adjunct diagnosis of papillary thyroid carcinoma.
Wang SL; Li SH; Chen WT; Chai CY
APMIS; 2007 Aug; 115(8):906-10. PubMed ID: 17696946
[TBL] [Abstract][Full Text] [Related]
18. Follicular thyroid lesions, elements that affect both diagnosis and prognosis.
Zeiger MA; Dackiw AP
J Surg Oncol; 2005 Mar; 89(3):108-13. PubMed ID: 15719377
[TBL] [Abstract][Full Text] [Related]
19. Pancreas cancer-associated antigen (PCAA) in medullary thyroid carcinoma.
Ueno K; Kobayashi T; Shimano T; Matsuura N; Monden T; Takeda T; Tomita N; Mori T
Med J Osaka Univ; 1994 Sep; 43(1-4):17-21. PubMed ID: 7609706
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies.
Gustafson KS; LiVolsi VA; Furth EE; Pasha TL; Putt ME; Baloch ZW
Am J Clin Pathol; 2003 Aug; 120(2):175-81. PubMed ID: 12931546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
